GS Finance Corp. has recently filed a pricing supplement for callable notes linked to the S&P 500 Futures Excess Return Index. This filing is significant as it reflects the company's ongoing efforts to engage investors in a competitive market for structured products. The notes are designed to offer returns based on the performance of the index, with the added feature of being callable by the issuer.
Founded as a subsidiary of The Goldman Sachs Group, Inc., GS Finance Corp. operates within the Security Brokers, Dealers & Flotation Companies sector. The company is incorporated in Delaware and has its headquarters at 200 West Street, New York, NY. The recent filing, dated October 30, 2026, falls under the SEC Act of 1933 and is part of a series of filings made on the same date.
The filing states, "The notes do not bear interest. The notes will mature on the stated maturity date (expected to be November 25, 2031), unless we redeem them." This indicates that the notes will not provide regular interest payments, which is a critical factor for potential investors to consider. Additionally, the notes may be redeemed at 100% of their face value plus a call premium, depending on the index performance.
This development could impact various stakeholders, including investors looking for structured products, as well as competitors within the security brokerage industry. The callable notes are expected to attract interest due to their unique structure and the backing of a reputable parent company, The Goldman Sachs Group, Inc.
Looking ahead, GS Finance Corp. may continue to issue additional notes or provide further details in subsequent filings. However, the current filing does not specify what actions will follow this pricing supplement.
Read Next
BP Sells 5% Stake in Aker BP for $1.06 Billion
WeRide Inc. Reports Stability in Share Capital Movements
Bullish Releases October 2026 Monthly Metrics Report
Chimera Investment Corp declares cash dividends for Q4 2026
Modern Mining Technology registers common shares on NYSE American
Innate Pharma Reports Q3 2026 Update, Highlights Pipeline Progress










